Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (26612)	10/12/2005 10:27:52 AM
From: manny t	Read Replies (2) \| Respond to of 48463

APNS, Isn't this huge news? APNS, Study Shows Applied NeuroSolutions' Test Improves Early Detection and Accurate Diagnosis of Alzheimer's Disease Wednesday October 12, 10:07 am ET VERNON HILLS, Ill.--(BUSINESS WIRE)--Oct. 12, 2005--A test developed by Applied NeuroSolutions (OTC BB:APNS - News; www.appliedneurosolutions.com) to detect Alzheimer's disease (AD) improves upon current methodologies by providing earlier and more accurate diagnosis of the disease, according to a study published in an upcoming issue of Neurobiology of Aging. ADVERTISEMENT The two-year study showed that by using Applied NeuroSolutions' test, which measures the amount of an abnormal protein, called p-tau 231 (tau protein phosphorylated on amino acid 231) in conjunction with current methods to diagnose Alzheimer's, scientists were able to accurately detect AD about 90 percent of the time. Doctors currently utilize memory tests and magnetic resonance imaging (MRI) to diagnose Alzheimer's, which is often misdiagnosed and confused with other neurological disorders, including depression and Parkinson's disease. The study, which followed patients with mild cognitive impairment (MCI) and a control group, showed that Applied NeuroSolutions' cerebrospinal fluid (CSF) test "consistently improved the diagnostic accuracy" of the other tests, the article stated. MCI is often a precursor to the development of AD. The data "support the concept that an accurate, reliable and possibly specific clinical diagnosis of AD in the MCI stage of clinical impairment is a reasonable expectation," the journal article concludes. Commenting on the study, Dr. John DeBernardis, President and CEO of Applied NeuroSolutions, said, "This study makes clear the important role that our test can play in definitively and accurately detecting Alzheimer's, especially early on in the progression of the disease." The study was conducted by a group of leading scientists in the AD field, including Dr. Peter Davies, who is the Judith and Burton P. Resnick Professor of Alzheimer's Disease Research at the Albert Einstein College of Medicine and the founding scientist of Applied NeuroSolutions. Applied NeuroSolutions, Inc. is developing products to diagnose and treat Alzheimer's disease based on a novel hypothesis of AD pathology. In partnership with Dr. Peter Davies and a scientific team at Albert Einstein College of Medicine, Applied NeuroSolutions has developed a cerebrospinal fluid (CSF) test to detect Alzheimer's disease at a very early stage with 85%-95% accuracy in more than 3,000 patient samples. There are approximately 2 million new patients annually worldwide who are candidates for an AD CSF diagnostic test, according to Datamonitor. In the U.S. alone, Datamonitor projects an $80 to $160 million annual market potential. The company is also developing a blood serum-based screening test, as well as a new class of therapeutics to treat AD. Alzheimer's disease currently afflicts over 4 million Americans, and the market for AD therapy is expected to grow to 21 million patients by 2010 in the seven major pharmaceutical markets (USA, France, Germany, Italy, Spain, U.K. and Japan) according to BioPortfolio, Ltd. There are currently no FDA-approved diagnostic tests to detect Alzheimer's disease. This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission. -------------------------------------------------------------------------------- Contact: Applied NeuroSolutions Company Contact: John F. DeBernardis, Ph.D. 847-573-8000 or Equity Communications Agency Contact: Ira Weingarten/Steve Chizzik 805-897-1880 or Monarch Communications Media Contact: Jeff Siegel, 516-569-4271 -------------------------------------------------------------------------------- Source: Applied NeuroSolutions